Biography and Research Information
OverviewAI-generated summary
Takeo Shibata's research focuses on cancer immunotherapy, reproductive immunology, and obstetrics and gynecology. His work investigates the role of T cells in the regression of cervical high-grade squamous intraepithelial lesions following therapeutic vaccine administration. Shibata has also explored methods for DNA extraction from liquid-based cytology specimens to facilitate the study of cervical microbiota.
His publications include research on the effectiveness of prophylactic HPV vaccines against cervical abnormalities in Japan, a retrospective study on immunotherapy for cervical cancer using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS), and a randomized clinical trial evaluating treatments for cervical intraepithelial neoplasia. Additionally, Shibata has contributed to studies examining associations between maternal postpartum depression and psychosocial factors, and the potential of amniotic fluid as a delivery route for substances during fetal development.
Shibata has received several awards, including the UAMS Student Research Day Poster Presentations (2nd place post-doctoral category) in 2020, the Kanazawa Medical University support group Tachibanakai Award in 2016, and the Kanazawa Medical University President's Award in 2016. He has a h-index of 12, with 64 publications and 485 total citations. Key collaborators at the University of Arkansas for Medical Sciences include Mayumi Nakagawa and Hannah Coleman.
Metrics
- h-index: 12
- Publications: 64
- Citations: 493
Selected Publications
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
-
Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3. (2024)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
-
Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed (2021)
-
Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota (2021)
Collaboration Network
Top Collaborators
Masahiro Takakura
Kanazawa Medical University (JP)
11 shared publications
- Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J‐HERS 2021 multicenter study
- Comparison of Aptima and hybrid capture‐2 HPV tests and Pap test in the referral population in Japan
- Associations between Maternal Postpartum Depression and Psychosocial Factors Including Marital Relationship and Social Support
- Amniotic fluid as a novel delivery route of 3-hydroxybutyrate during fetal brain development
- A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer
Showing 5 of 11 shared publications
Toshiyuki Sasagawa
Kanazawa Medical University (JP)
11 shared publications
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J‐HERS 2021 multicenter study
- Comparison of Aptima and hybrid capture‐2 HPV tests and Pap test in the referral population in Japan
- Associations between Maternal Postpartum Depression and Psychosocial Factors Including Marital Relationship and Social Support
Showing 5 of 11 shared publications
Jinichi Sakamoto
Kanazawa University (JP)
7 shared publications
- Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J‐HERS 2021 multicenter study
- Comparison of Aptima and hybrid capture‐2 HPV tests and Pap test in the referral population in Japan
- Associations between Maternal Postpartum Depression and Psychosocial Factors Including Marital Relationship and Social Support
- A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer
- Chemical Peeling Therapy Using Phenol for the Cervico-Vaginal Intraepithelial Neoplasia
Showing 5 of 7 shared publications
Mayumi Nakagawa
University of Arkansas for Medical Sciences
5 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Hannah Coleman
University of Arkansas for Medical Sciences
5 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Emi Takata
Kanazawa Medical University (JP)
5 shared publications
- Associations between Maternal Postpartum Depression and Psychosocial Factors Including Marital Relationship and Social Support
- Amniotic fluid as a novel delivery route of 3-hydroxybutyrate during fetal brain development
- A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer
- High 3-hydroxybutyrate concentrations in the placenta-produced amniotic fluid in the human uterus
- Effectiveness of prophylactic HPV vaccine for cervical abnormalities and HPV infection in Japan: the Japanese Human Papillomavirus Disease Education and Research Survey (J-HERS) 2021
William W. Greenfield
University of Arkansas for Medical Sciences
4 shared publications
In database
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Teresa Evans
University of Arkansas for Medical Sciences
4 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Yong‐Chen Lu
University of Arkansas for Medical Sciences
4 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- Immune responses in a phase 2 clinical trial of peptide-based therapeutic human papillomavirus vaccine, PepCan, versus <i>Candida</i> adjuvant alone in treating cervical intraepithelial neoplasia 2/3.
Sohsuke Yamada
Kanazawa Medical University (JP)
4 shared publications
- Amniotic fluid as a novel delivery route of 3-hydroxybutyrate during fetal brain development
- A retrospective study of immunotherapy using the cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin (BCG-CWS) for cervical cancer
- High 3-hydroxybutyrate concentrations in the placenta-produced amniotic fluid in the human uterus
- Clinical Trial on the Safety and Tolerability of Personalized Cancer Vaccines Using Human Platelet Lysate-Induced Antigen-Presenting Cells
Toshiyuki Maehama
Okinawa Prefecture (JP)
4 shared publications
- Effectiveness of prophylactic HPV vaccines against cervical abnormalities and HPV infection in Japan: The J‐HERS 2021 multicenter study
- Chemical Peeling Therapy Using Phenol for the Cervico-Vaginal Intraepithelial Neoplasia
- Phenol-based Chemical Peeling Therapy for Cervico-vaginal Intraepithelial Neoplasia (CIN/VaIN)
- Effectiveness of prophylactic HPV vaccine for cervical abnormalities and HPV infection in Japan: the Japanese Human Papillomavirus Disease Education and Research Survey (J-HERS) 2021
Michael S. Robeson
University of Arkansas for Medical Sciences
3 shared publications
In database
- Evaluation of DNA extraction protocols from liquid-based cytology specimens for studying cervical microbiota
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Sumit K. Shah
University of Arkansas for Medical Sciences
3 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Benjamin J. Lieblong
University of Arkansas for Medical Sciences
3 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Charles M. Quick
University of Arkansas for Medical Sciences
3 shared publications
In database
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Similar Researchers
Based on overlapping research topics
William W. Greenfield
University of Arkansas for Medical Sciences
Cervical Cancer and HPV Research
Maternal and Perinatal Health Interventions
Immune Response and Inflammation
Mayumi Nakagawa
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Cervical Cancer and HPV Research
Immune Response and Inflammation
Brian Russ
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Maternal and Perinatal Health Interventions
Immune Response and Inflammation
Bhagyashri Bhende
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Microbial infections and disease research
Health Sciences Research and Education
Wadhah M. Bin Homam
University of Arkansas for Medical Sciences
Cancer Immunotherapy and Biomarkers
Immune Response and Inflammation
Microbial infections and disease research
Kayla Mohr
University of Arkansas for Medical Sciences
Immune Response and Inflammation
Microbial infections and disease research
Health Sciences Research and Education